Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis

Xinhua Chen, Zhiyuan Chen, Andrew S. Azman, Xiaowei Deng, Xinghui Chen, Wanying Lu, Zeyao Zhao, Juan Yang, Cecile Viboud, Marco Ajelli, Daniel T. Leung, Hongjie Yu
doi: https://doi.org/10.1101/2020.09.11.20192773
Xinhua Chen
1School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiyuan Chen
1School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew S. Azman
2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
3Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Switzerland
4Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaowei Deng
1School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinghui Chen
1School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wanying Lu
1School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zeyao Zhao
1School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Yang
1School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecile Viboud
5Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Ajelli
6Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel T. Leung
7Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongjie Yu
1School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yhj@fudan.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background A rapidly increasing number of serological surveys for anti-SARS-CoV-2 antibodies have been reported worldwide. A synthesis of this large corpus of data is needed.

Purpose To evaluate the quality of serological studies and provide a global picture of seroprevalence across demographic and occupational groups, and to provide guidance for conducting better serosurveys.

Data sources We searched PubMed, Embase, Web of Science, and 4 pre-print servers for English-language papers published from December 1, 2019 to September 25, 2020.

Study selection Serological studies evaluating SARS-CoV-2 seroprevalence in humans.

Data extraction Two investigators independently extracted data from studies.

Data Synthesis Most of 230 serological studies, representing tests in >1,400,000 individuals, identified were of low quality based on a standardized study quality scale. In the 51 studies of higher quality, high-risk healthcare workers had higher seroprevalence of 17.1% (95% CI: 9.9-24.4%), compared to low-risk healthcare workers and general population of 5.4% (0.7-10.1%) and 5.3% (4.2-6.4%). Seroprevalence varied hugely across WHO regions, with lowest seroprevalence of general population in Western Pacific region (1.7%, 0.0-5.0%). Generally, the young (<20 years) and the old (≥65 years) were less likely to be seropositive compared to middle-aged (20-64 years) populations.

Seroprevalence correlated with clinical COVID-19 reports, with pooled average of 7.7 (range: 2.0 to 23.1) serologically-detected-infections per confirmed COVID-19 case.

Limitations Some heterogeneity cannot be well explained quantitatively.

Conclusions The overall quality of seroprevalence studies examined was low. The relatively low seroprevalence among general populations suggest that in most settings, antibody-mediated herd immunity is far from being reached. Given the relatively narrow range of estimates of the ratio of serologically-detected infections to confirmed cases across different locales, reported case counts may help provide insights into the true proportion of the population infected.

Primary Funding source National Science Fund for Distinguished Young Scholars (PROSPERO: CRD42020198253).

Competing Interest Statement

H.Y. has received investigator-initiated research funding from Sanofi Pasteur, GlaxoSmithKline, and Yichang HEC Changjiang Pharmaceutical Company; M.A. has received research funding from Seqirus; D.T.L. and A.S.A. has received research funding from the US National Institutes of Health. None of those research funding is related to COVID-19. All other authors report no competing interests.

Funding Statement

This study was funded by the National Science Fund for Distinguished Young Scholars (grant no. 81525023), Program of Shanghai Academic/Technology Research Leader (grant no. 18XD1400300), National Science and Technology Major project of China (grant no. 2018ZX10713001-007, 2017ZX10103009-005, 2018ZX10201001-010), the US National Institutes of Health (R01 AI135115 to D.T.L. and A.S.A.)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This review was preregistered with the protocol available in the PROSPERO database (ID: CRD42020198253).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclaimer: The views expressed are those of the authors and do not necessarily represent the institutions with which the authors are affiliated.

Data Availability

All data referred to in the manuscript was available in appendix.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 29, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
Xinhua Chen, Zhiyuan Chen, Andrew S. Azman, Xiaowei Deng, Xinghui Chen, Wanying Lu, Zeyao Zhao, Juan Yang, Cecile Viboud, Marco Ajelli, Daniel T. Leung, Hongjie Yu
medRxiv 2020.09.11.20192773; doi: https://doi.org/10.1101/2020.09.11.20192773
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
Xinhua Chen, Zhiyuan Chen, Andrew S. Azman, Xiaowei Deng, Xinghui Chen, Wanying Lu, Zeyao Zhao, Juan Yang, Cecile Viboud, Marco Ajelli, Daniel T. Leung, Hongjie Yu
medRxiv 2020.09.11.20192773; doi: https://doi.org/10.1101/2020.09.11.20192773

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (195)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5674)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (863)
  • Geriatric Medicine (88)
  • Health Economics (230)
  • Health Informatics (761)
  • Health Policy (390)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6467)
  • Intensive Care and Critical Care Medicine (390)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (846)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (162)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (113)
  • Psychiatry and Clinical Psychology (963)
  • Public and Global Health (2224)
  • Radiology and Imaging (376)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)